Acute Respiratory Distress Syndrome (ARDS)APRiCENCT02167698
Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia
A study testing Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation and Methylprednisolone in people with Acute Respiratory Distress Syndrome (ARDS), run by Post Graduate Institute of Medical Education and Research, Chandigarh at 1 site in India.
Trial summary
This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality. Moreover, most of the studies are adult-based and have been extrapolated to children. Read more about this study
- Who is it for?
- Ages 1 month to 12 years
- Conditions the study is for
- Acute Respiratory Distress Syndrome (ARDS)
- What is being tested?
- Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation and Methylprednisolone
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- 1 siteIndia
- Study dates
- Feb 2014to Dec 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children aged 1 month- 12 years, who are intubated and mechanically ventilated with the following criteria of Acute Respiratory Distress Syndrome:
- Acute presentation within 1 week of a known clinical insult or new/ worsening respiratory symptoms
- Bilateral opacities on chest imaging - not fully explained by effusions, lobar/lung collapse, or nodules
- Respiratory failure is not fully explained by cardiac failure or fluid overload (Echocardiographic assessment to exclude hydrostatic edema)
- Impaired oxygenation with PaO2/ FiO2 ratio less than 300 or Oxygenation Index greater than 5.3
Who cannot join
- Greater than 24 hours since diagnosis of ARDS
- Co-existing raised intra-cranial pressure/ any other condition necessitating use of high dose of sedation (likely to suppress spontaneous breathing)
- Radiologically confirmed air leak prior to randomization - Pneumothorax/ Pulmonary interstitial Emphysema
- Clinical evidence of significant airway obstruction/ severe bronchospasm / reactive airway disease
- Have received mechanical ventilation for more than 72 hours (before meeting inclusion criteria)
- Symptomatic or uncorrected congenital heart disease or a right to left intra-cardiac shunt
- Any underlying condition that is likely to impair spontaneous respiratory drive/ efforts (Eg: Brainstem dysfunction, neuromuscular paralysis)
- Underlying chronic diseases (Eg: Cystic fibrosis, Chronic lung disease, etc)
Trial locations and contacts
1 site in 1 country.
India1 site
Pediatric Intensive care unit, Division of Pediatric Critical Care, Advanced Pediatrics Center, Post-graduate Institute of Medical Education & Research
Chandigarh, 160012
About this study
Official title: A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome
This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality. Moreover, most of the studies are adult-based and have been extrapolated to children. Airway pressure release ventilation (APRV) mode is hypothesized to be superior in terms of lower need for sedation, shorter duration of mechanical ventilation, etc. It is unique and the first worldwide randomized controlled trial on APRV mode in children.
We plan to recruit a minimum of 50 children aged (1 month-12 years) in each group. The study is to be conducted at the Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh between March 2014 to March 2016. This trial would recruit children with respiratory failure and early ARDS and, randomize them to receive either conventional ventilation or the APRV mode. Rest of the supportive care has also been protocolized so that both groups receive treatment as per the existing best practices in every aspect. The primary outcome being studied is the number of ventilator-free days. The secondary outcomes include length of PICU stay, hospital stay, organ-failure free days, 28 day \& 3 month survival, biomarkers of lung injury (IL-6, IL-8, Angiopoeitin-2, soluble-ICAM-1, etc), functional status, Pulmonary function tests, etc. Funding request would be sent to the Indian Council of Medical Research, New Delhi, India.
Assessing lung biomarkers like Interleukin-6 would assess the role of different modes of ventilation in acting as triggers for multi-organ dysfunction as well as for worsening lung injury. This pathbreaking research is likely to open up new avenues upon completion.
Read the detailed description
Study setting:
15-bedded pediatric intensive care unit (PICU) of a multi-specialty, tertiary referral and teaching hospital- the Advanced Pediatrics Centre (APC) in Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India Study period Recruitment: January 2014 to December 2016 Data Analysis: Jan 2017 to June 2017 Study design An open-labelled, parallel-arm, efficacy/feasibility randomized controlled trial Ethics approval Ethics approval has been obtained from the Institute Ethics Committee. The study has been registered with Clinical Trials Registry - India (CTRI) (ctri.nic.in). Informed consent will be obtained from the parents/legal guardian and the conversation would be recorded using a camera (audio-visual documentation of evidence).
Sample size estimation Assuming alpha error of 5% and power of 80% with non-inferiority limit of 4 days (Standard deviation of VFDs being 8.2 days in the conventional low tidal volume ventilation group in pilot trial), sample size was calculated to be 52 per group. As this is a safety and feasibility trial, an interim analysis would be done at 50% enrolment.
Enrolment Parents or legal guardians of children who satisfy the above eligibility criteria will be invited by the investigator to participate in the study. Parents are free not to participate, or to withdraw from the study at any point of time. All children, irrespective of their enrollment in the study, will receive standard pediatric intensive care unit (PICU) care as per the unit's existing protocol. An information sheet (in Hindi/ English) furnishing details of the study will be provided to the parents. Given the fact that all these children are sedated and on mechanical ventilation, obtaining assent would not be feasible in this study.
Randomization Sequence generation A computer-generated, unstratified, block randomization with variable block sizes will be performed to determine group allocation. A person not involved in the study will perform the random number allocation and prepare opaque, sealed envelopes containing the allocation.
Concealment allocation Each pre-sealed opaque envelope would be opened only after obtaining a written consent and audio-visual record of the same. As the randomization is done using a variable block size, and prepared by a statistician not directly involved in the study, there would be no way of predicting the random allocation, thus minimizing the risk of allocation bias.
Randomization implementation After parents provide informed consent, randomization would be done within the next one hour and child initiated on appropriate mode of ventilation. The supportive care for both the groups, would be as per the attached supplementary protocols
Intervention protocol:
The Airway pressure release ventilation (APRV) intervention protocol has been designed based on the available APRV literature as of Dec 2013.
Start the child on APRV mode of ventilation with the following settings:
- P HIGH would determine the degree of baseline lung inflation. A rough estimate can be obtained based on the plateau pressure requirements on the conventional mode of ventilation. Perform an inspiratory hold to ascertain the plateau pressures:
- If P plateau > 30 cm water, set P HIGH at 30 cm water
- If P plateau < 30 cm water, set P HIGH at or 1-2 cm above the measured P plateau.
- Alternatively, if P plateau cannot be measured, P HIGH can be set according to the following guide:
PaO2/ FiO2 ratio P High < 250 15-20 < 200 20-25 < 150 25-28
After initiating a particular P HIGH, a clinical assessment of lung volume needs to be followed with a chest radiograph to determine the degree of lung inflation (similar to setting of Mean airway pressure in High frequency oscillatory mode of ventilation). The child's P HIGH is adjusted to maintain optimal lung volume, without clinical or radiological evidence of hyperinflation: no signs of decreased cardiac output/ hypotension and/or the level of the diaphragm visible greater than the ninth rib.
- Start at T High of 4 seconds; Titrate T High based on oxygenation status. At least 80 -95% of the total cycle time should be spent in T High.
- Set P Low at Zero cm H2O
- Set T Low so that expiratory flow decreases by 25 % of peak expiratory flow rate (PEFR); usually 0.1-0.8 seconds. The ratio of T-PEFR to PEFR should be targeted near 75%. This entity needs to be titrated every 2-4 hours and may have to be shortened as lung injury advances.
- Set Pressure Support at ZERO
- The number of breaths per minute or number of releases is a function of T High and T Low as depicted below:
Weaning from APRV would also be carried out in a structured, protocolized manner. The following strategies would be adopted:
- As child's clinical condition and oxygenation index improves, and Fraction of inspired oxygen levels are brought down to 0.6, T HIGH is increased in steps of 0.5-2 seconds till it is 10-12 seconds.
- P HIGH can be subsequently decreased in steps of 2-3 cm H2O till a value of 12-16 is reached. Decrease in P HIGH can be carried out earlier if features of hyperinflation (clinical/radiological) appear at any point.
- The goal is to reach pressure levels of 12-16 cm H2O and then switch to Continuous positive airway pressure (CPAP) of 6-8 cm H2O, from which child can be extubated directly to nasal prong CPAP or gradually tapered off CPAP to Endotracheal-T piece and subsequently extubated depending on the overall clinical status.
- Being tested
- Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation, Methylprednisolone, Restrictive fluid therapy, sedo-analgesia titration
- Keywords
- Pediatric acute respiratory distress syndrome, Mechanical ventilation, Airway pressure release ventilation, Conventional low-tidal volume ventilation
- Medical subject headings
- Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Airway Pressure Release Ventilation (APRV)Device
Also called BiLevel, BiPAP
This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
Low-tidal volume ventilationOther
Also called Lung-protective ventilation
This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
Restrictive fluid therapyOther
Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols
sedo-analgesia titrationDrug
Protocolized early enteral nutritionOther
Early enteral nutrition and attempt to meet calorie-protein goals
Protocolized supportive careOther
Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
Biomarker AssayOther
Also called Interleukin 6, Interleukin 8, Angiopoeitin-2, soluble-ICAM-1
Biomarker Assay for patients in both arms
| Study group | Role | What they receive |
|---|---|---|
| Airway pressure release ventilation arm | Experimental | This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode.
Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups. Receives: Device: Airway Pressure Release Ventilation (APRV); Drug: Methylprednisolone; Other: Restrictive fluid therapy; Drug: sedo-analgesia titration; Other: Protocolized early enteral nutrition; Other: Protocolized supportive care; Other: Biomarker Assay |
| Low-tidal volume ventilation arm | Active comparator | Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups Receives: Other: Low-tidal volume ventilation; Drug: Methylprednisolone; Other: Restrictive fluid therapy; Drug: sedo-analgesia titration; Other: Protocolized early enteral nutrition; Other: Protocolized supportive care; Other: Biomarker Assay |
What is being measured
The primary outcome is the main question the study is designed to answer.
Twenty-eight-day ventilator-free days
Measured: 28 days
Secondary outcomes (23)
Twenty-eight-day survival
Measured: 28 days
Length of PICU stay
The children would be followed up for the duration of their PICU stay
Measured: Up to 3 months
Organ-failure-free-days
Measured: 28 days
Time-to-recovery of lung injury
Number of days for recovery of lung injury (OI<5).
Measured: Up to 28 days
Number of children with adverse events
Children would be observed for incidence of adverse events during the period of PICU stay/ ventilation
Measured: 3 years
All-cause mortality
Measured: Three months
Spirometry
Forced Expiratory volume during 1st second/ Forced vital capacity
Measured: 3 months
Pediatric Cerebral performance category
Functional outcomes
Measured: 6 Months
Pediatric Overall performance category
Measured: 6 months
Spirometry
Forced Expiratory Volume during 1st second / Forced Vital Capacity
Measured: 6 months
Pediatric overall performance category
Assessment of functional outcomes
Measured: 3 months
Pediatric cerebral performance category
Assessment of functional outcomes
Measured: 3 months
Interleukin-6 levels
Measured: 72 hours of enrolment
Arterial lactate levels
Measured: 72 hours
Percentage reduction in 'oxygenation Index'
Percentage improvement in oxygenation index at 6 hours of enrolment
Measured: 6 hours
Radiological score
Measured: 48 hours
Duration of inotropic requirement
Average time frame
Measured: up to 7 days
Vaso-active inotropic score
Measured: 72 hours
Cumulative dose of sedation
Measured: 7 days
Cumulative dose of analgesic
Measured: 7 days
Cumulative dose of neuromuscular blocking agent
Measured: 7 days
Requirement for renal replacement therapy
Need for renal replacement therapy in the first 28 days of PICu stay or discharge/ death whichever is earlier
Measured: 28 days
Pediatric Logistic Organ Dysfunction (PELOD) score
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jun 2014 (estimated)
- Study startFeb 2014
- Primary completionJun 2016
- Study completionDec 2016
Why it stopped: Increased mortality in the intervention arm at 50% enrolment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Acute Respiratory Distress Syndrome (ARDS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 52 participants (actual)
Sponsor and investigators
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Saptharishi L G, MBBS, MD, Post Graduate Institute of Medical Education and Research, Chandigarh
- Investigators
- Saptharishi L G, MBBS, MD, Principal investigator, DM (Pediatric Critical Care) Senior Resident, Division of Pediatric critical care, Dept Of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, INDIAJayashree Muralidharan, MBBS, MD, Study chair, Additional Professor, Division of Pediatric critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, IndiaSunit C Singhi, MBBS, MD, Study director, Chief, Division of Pediatric Critical Care, Professor & Head, Department of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, IndiaArun Bansal, MBBS, MD, Study chair, Assistant Professor, Division of Pediatric Critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02167698
- Sponsor's protocol ID
- CTRI/2014/06/004677
- Other IDs
- CTRI/2014/06/004677
- Acronym
- APRiCE
- Status last verified
- May 2017
- First submitted
- 16 Jun 2014
- Last updated
- 19 May 2017
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided: Permission would have to be sought from institution in this regard.
Publications
Andrews P, Habashi N. Airway pressure release ventilation. Curr Probl Surg. 2013 Oct;50(10):462-70. doi: 10.1067/j.cpsurg.2013.08.010. No abstract available.
PubMed 24156844Andrews PL, Shiber JR, Jaruga-Killeen E, Roy S, Sadowitz B, O'Toole RV, Gatto LA, Nieman GF, Scalea T, Habashi NM. Early application of airway pressure release ventilation may reduce mortality in high-risk trauma patients: a systematic review of observational trauma ARDS literature. J Trauma Acute Care Surg. 2013 Oct;75(4):635-41. doi: 10.1097/TA.0b013e31829d3504.
PubMed 24064877Emr B, Gatto LA, Roy S, Satalin J, Ghosh A, Snyder K, Andrews P, Habashi N, Marx W, Ge L, Wang G, Dean DA, Vodovotz Y, Nieman G. Airway pressure release ventilation prevents ventilator-induced lung injury in normal lungs. JAMA Surg. 2013 Nov;148(11):1005-12. doi: 10.1001/jamasurg.2013.3746.
PubMed 24026214Roy SK, Emr B, Sadowitz B, Gatto LA, Ghosh A, Satalin JM, Snyder KP, Ge L, Wang G, Marx W, Dean D, Andrews P, Singh A, Scalea T, Habashi N, Nieman GF. Preemptive application of airway pressure release ventilation prevents development of acute respiratory distress syndrome in a rat traumatic hemorrhagic shock model. Shock. 2013 Sep;40(3):210-6. doi: 10.1097/SHK.0b013e31829efb06.
PubMed 23799354Roy S, Habashi N, Sadowitz B, Andrews P, Ge L, Wang G, Roy P, Ghosh A, Kuhn M, Satalin J, Gatto LA, Lin X, Dean DA, Vodovotz Y, Nieman G. Early airway pressure release ventilation prevents ARDS-a novel preventive approach to lung injury. Shock. 2013 Jan;39(1):28-38. doi: 10.1097/SHK.0b013e31827b47bb.
PubMed 23247119Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, Bansal A. Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1199-1207. doi: 10.1164/rccm.201705-0989OC.
PubMed 29641221
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome
- ClinicalTrials.gov ID
- NCT02167698
- Acronym / sponsor ID
- APRiCE / CTRI/2014/06/004677
- Keywords
- Pediatric acute respiratory distress syndrome, Mechanical ventilation, Airway pressure release ventilation, Conventional low-tidal volume ventilation
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Increased mortality in the intervention arm at 50% enrolment
- Enrolment
- 52 participants (actual)
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, ChandigarhUniversity, hospital or other
- Study start
- Feb 2014
- Primary completion
- Jun 2016 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 19 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality. Moreover, most of the studies are adult-based and have been extrapolated to children. Airway pressure release ventilation (APRV) mode is hypothesized to be superior in terms of lower need for sedation, shorter duration of mechanical ventilation, etc. It is unique and the first worldwide randomized controlled trial on APRV mode in children.
We plan to recruit a minimum of 50 children aged (1 month-12 years) in each group. The study is to be conducted at the Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh between March 2014 to March 2016. This trial would recruit children with respiratory failure and early ARDS and, randomize them to receive either conventional ventilation or the APRV mode. Rest of the supportive care has also been protocolized so that both groups receive treatment as per the existing best practices in every aspect. The primary outcome being studied is the number of ventilator-free days. The secondary outcomes include length of PICU stay, hospital stay, organ-failure free days, 28 day \& 3 month survival, biomarkers of lung injury (IL-6, IL-8, Angiopoeitin-2, soluble-ICAM-1, etc), functional status, Pulmonary function tests, etc. Funding request would be sent to the Indian Council of Medical Research, New Delhi, India.
Assessing lung biomarkers like Interleukin-6 would assess the role of different modes of ventilation in acting as triggers for multi-organ dysfunction as well as for worsening lung injury. This pathbreaking research is likely to open up new avenues upon completion.
Detailed description
Study setting:
15-bedded pediatric intensive care unit (PICU) of a multi-specialty, tertiary referral and teaching hospital- the Advanced Pediatrics Centre (APC) in Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India Study period Recruitment: January 2014 to December 2016 Data Analysis: Jan 2017 to June 2017 Study design An open-labelled, parallel-arm, efficacy/feasibility randomized controlled trial Ethics approval Ethics approval has been obtained from the Institute Ethics Committee. The study has been registered with Clinical Trials Registry - India (CTRI) (ctri.nic.in). Informed consent will be obtained from the parents/legal guardian and the conversation would be recorded using a camera (audio-visual documentation of evidence).
Sample size estimation Assuming alpha error of 5% and power of 80% with non-inferiority limit of 4 days (Standard deviation of VFDs being 8.2 days in the conventional low tidal volume ventilation group in pilot trial), sample size was calculated to be 52 per group. As this is a safety and feasibility trial, an interim analysis would be done at 50% enrolment.
Enrolment Parents or legal guardians of children who satisfy the above eligibility criteria will be invited by the investigator to participate in the study. Parents are free not to participate, or to withdraw from the study at any point of time. All children, irrespective of their enrollment in the study, will receive standard pediatric intensive care unit (PICU) care as per the unit's existing protocol. An information sheet (in Hindi/ English) furnishing details of the study will be provided to the parents. Given the fact that all these children are sedated and on mechanical ventilation, obtaining assent would not be feasible in this study.
Randomization Sequence generation A computer-generated, unstratified, block randomization with variable block sizes will be performed to determine group allocation. A person not involved in the study will perform the random number allocation and prepare opaque, sealed envelopes containing the allocation.
Concealment allocation Each pre-sealed opaque envelope would be opened only after obtaining a written consent and audio-visual record of the same. As the randomization is done using a variable block size, and prepared by a statistician not directly involved in the study, there would be no way of predicting the random allocation, thus minimizing the risk of allocation bias.
Randomization implementation After parents provide informed consent, randomization would be done within the next one hour and child initiated on appropriate mode of ventilation. The supportive care for both the groups, would be as per the attached supplementary protocols
Intervention protocol:
The Airway pressure release ventilation (APRV) intervention protocol has been designed based on the available APRV literature as of Dec 2013.
Start the child on APRV mode of ventilation with the following settings:
- P HIGH would determine the degree of baseline lung inflation. A rough estimate can be obtained based on the plateau pressure requirements on the conventional mode of ventilation. Perform an inspiratory hold to ascertain the plateau pressures:
- If P plateau > 30 cm water, set P HIGH at 30 cm water
- If P plateau < 30 cm water, set P HIGH at or 1-2 cm above the measured P plateau.
- Alternatively, if P plateau cannot be measured, P HIGH can be set according to the following guide:
PaO2/ FiO2 ratio P High < 250 15-20 < 200 20-25 < 150 25-28
After initiating a particular P HIGH, a clinical assessment of lung volume needs to be followed with a chest radiograph to determine the degree of lung inflation (similar to setting of Mean airway pressure in High frequency oscillatory mode of ventilation). The child's P HIGH is adjusted to maintain optimal lung volume, without clinical or radiological evidence of hyperinflation: no signs of decreased cardiac output/ hypotension and/or the level of the diaphragm visible greater than the ninth rib.
- Start at T High of 4 seconds; Titrate T High based on oxygenation status. At least 80 -95% of the total cycle time should be spent in T High.
- Set P Low at Zero cm H2O
- Set T Low so that expiratory flow decreases by 25 % of peak expiratory flow rate (PEFR); usually 0.1-0.8 seconds. The ratio of T-PEFR to PEFR should be targeted near 75%. This entity needs to be titrated every 2-4 hours and may have to be shortened as lung injury advances.
- Set Pressure Support at ZERO
- The number of breaths per minute or number of releases is a function of T High and T Low as depicted below:
Weaning from APRV would also be carried out in a structured, protocolized manner. The following strategies would be adopted:
- As child's clinical condition and oxygenation index improves, and Fraction of inspired oxygen levels are brought down to 0.6, T HIGH is increased in steps of 0.5-2 seconds till it is 10-12 seconds.
- P HIGH can be subsequently decreased in steps of 2-3 cm H2O till a value of 12-16 is reached. Decrease in P HIGH can be carried out earlier if features of hyperinflation (clinical/radiological) appear at any point.
- The goal is to reach pressure levels of 12-16 cm H2O and then switch to Continuous positive airway pressure (CPAP) of 6-8 cm H2O, from which child can be extubated directly to nasal prong CPAP or gradually tapered off CPAP to Endotracheal-T piece and subsequently extubated depending on the overall clinical status.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Airway pressure release ventilation arm | Experimental | Device: Airway Pressure Release Ventilation (APRV), Drug: Methylprednisolone, Other: Restrictive fluid therapy, Drug: sedo-analgesia titration, Other: Protocolized early enteral nutrition, Other: Protocolized supportive care, Other: Biomarker AssayThis group of children would be ventilated using the Airway pressure release ventilation (APRV) mode. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups. |
| Low-tidal volume ventilation arm | Active comparator | Other: Low-tidal volume ventilation, Drug: Methylprednisolone, Other: Restrictive fluid therapy, Drug: sedo-analgesia titration, Other: Protocolized early enteral nutrition, Other: Protocolized supportive care, Other: Biomarker AssayLow-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups |
Who may qualify
- Ages
- 1 month to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Children aged 1 month- 12 years, who are intubated and mechanically ventilated with the following criteria of Acute Respiratory Distress Syndrome:
Key exclusion criteria (8 listed)
- Greater than 24 hours since diagnosis of ARDS
- Co-existing raised intra-cranial pressure/ any other condition necessitating use of high dose of sedation (likely to suppress spontaneous breathing)
- Radiologically confirmed air leak prior to randomization - Pneumothorax/ Pulmonary interstitial Emphysema
- Clinical evidence of significant airway obstruction/ severe bronchospasm / reactive airway disease
- Have received mechanical ventilation for more than 72 hours (before meeting inclusion criteria)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Airway Pressure Release Ventilation (APRV)Also: BiLevel, BiPAPThis is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation | Device | Airway pressure release ventilation arm |
| Low-tidal volume ventilationAlso: Lung-protective ventilationThis mode of ventilation is the standard of care worldwide for ventilating children with ARDS. | Other | Low-tidal volume ventilation arm |
| MethylprednisoloneChildren with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion. | Drug | Airway pressure release ventilation arm, Low-tidal volume ventilation arm |
| Restrictive fluid therapyFluid \& hemodynamics would be titrated as per pre-designed decision-making protocols | Other | Airway pressure release ventilation arm, Low-tidal volume ventilation arm |
| sedo-analgesia titration | Drug | Airway pressure release ventilation arm, Low-tidal volume ventilation arm |
| Protocolized early enteral nutritionEarly enteral nutrition and attempt to meet calorie-protein goals | Other | Airway pressure release ventilation arm, Low-tidal volume ventilation arm |
| Protocolized supportive careEye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care | Other | Airway pressure release ventilation arm, Low-tidal volume ventilation arm |
| Biomarker AssayAlso: Interleukin 6, Interleukin 8, Angiopoeitin-2, soluble-ICAM-1Biomarker Assay for patients in both arms | Other | Airway pressure release ventilation arm, Low-tidal volume ventilation arm |
Primary outcome
Twenty-eight-day ventilator-free days
Time frame: 28 days
23 secondary outcomes
Twenty-eight-day survival
Time frame: 28 days
Length of PICU stay
Time frame: Up to 3 months
Organ-failure-free-days
Time frame: 28 days
Time-to-recovery of lung injury
Time frame: Up to 28 days
Number of children with adverse events
Time frame: 3 years
All-cause mortality
Time frame: Three months
Spirometry
Time frame: 3 months
Pediatric Cerebral performance category
Time frame: 6 Months
Pediatric Overall performance category
Time frame: 6 months
Spirometry
Time frame: 6 months
Pediatric overall performance category
Time frame: 3 months
Pediatric cerebral performance category
Time frame: 3 months
Interleukin-6 levels
Time frame: 72 hours of enrolment
Arterial lactate levels
Time frame: 72 hours
Percentage reduction in 'oxygenation Index'
Time frame: 6 hours
Radiological score
Time frame: 48 hours
Duration of inotropic requirement
Time frame: up to 7 days
Vaso-active inotropic score
Time frame: 72 hours
Cumulative dose of sedation
Time frame: 7 days
Cumulative dose of analgesic
Time frame: 7 days
Cumulative dose of neuromuscular blocking agent
Time frame: 7 days
Requirement for renal replacement therapy
Time frame: 28 days
Pediatric Logistic Organ Dysfunction (PELOD) score
Time frame: 7 days
Results and safety
The study was stopped early (reason given: Increased mortality in the intervention arm at 50% enrolment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2017.
- Background: PubMed 24156844Andrews P, Habashi N. Airway pressure release ventilation. Curr Probl Surg. 2013 Oct;50(10):462-70. doi: 10.1067/j.cpsurg.2013.08.010. No abstract available.
- Background: PubMed 24064877Andrews PL, Shiber JR, Jaruga-Killeen E, Roy S, Sadowitz B, O'Toole RV, Gatto LA, Nieman GF, Scalea T, Habashi NM. Early application of airway pressure release ventilation may reduce mortality in high-risk trauma patients: a systematic review of observational trauma ARDS literature. J Trauma Acute Care Surg. 2013 Oct;75(4):635-41. doi: 10.1097/TA.0b013e31829d3504.
- Background: PubMed 24026214Emr B, Gatto LA, Roy S, Satalin J, Ghosh A, Snyder K, Andrews P, Habashi N, Marx W, Ge L, Wang G, Dean DA, Vodovotz Y, Nieman G. Airway pressure release ventilation prevents ventilator-induced lung injury in normal lungs. JAMA Surg. 2013 Nov;148(11):1005-12. doi: 10.1001/jamasurg.2013.3746.
- Background: PubMed 23799354Roy SK, Emr B, Sadowitz B, Gatto LA, Ghosh A, Satalin JM, Snyder KP, Ge L, Wang G, Marx W, Dean D, Andrews P, Singh A, Scalea T, Habashi N, Nieman GF. Preemptive application of airway pressure release ventilation prevents development of acute respiratory distress syndrome in a rat traumatic hemorrhagic shock model. Shock. 2013 Sep;40(3):210-6. doi: 10.1097/SHK.0b013e31829efb06.
- Background: PubMed 23247119Roy S, Habashi N, Sadowitz B, Andrews P, Ge L, Wang G, Roy P, Ghosh A, Kuhn M, Satalin J, Gatto LA, Lin X, Dean DA, Vodovotz Y, Nieman G. Early airway pressure release ventilation prevents ARDS-a novel preventive approach to lung injury. Shock. 2013 Jan;39(1):28-38. doi: 10.1097/SHK.0b013e31827b47bb.
- Derived from this study: PubMed 29641221Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, Bansal A. Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1199-1207. doi: 10.1164/rccm.201705-0989OC.
- Individual participant dataSharing planned: Undecided. Permission would have to be sought from institution in this regard.
Related trials for Acute Respiratory Distress Syndrome (ARDS)
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruitingObservational study
Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping
Acute Respiratory Distress Syndrome
RecruitingObservational study
Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)
ARDS
Recruiting
Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants
Surfactant, Respiratory Distress Syndrome (Neonatal)
Recruiting
REspiratory MEchanics for Delivering Individualised Exogenous Surfactant
Respiratory Distress Syndrome in Premature Infant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Saptharishi L G, MBBS, MD principal investigator
DM (Pediatric Critical Care) Senior Resident, Division of Pediatric critical care, Dept Of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, INDIA
Jayashree Muralidharan, MBBS, MD study chair
Additional Professor, Division of Pediatric critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India
Sunit C Singhi, MBBS, MD study director
Chief, Division of Pediatric Critical Care, Professor & Head, Department of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation and Methylprednisolone in people with Acute Respiratory Distress Syndrome (ARDS), run by Post Graduate Institute of Medical Education and Research, Chandigarh at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 19 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Increased mortality in the intervention arm at 50% enrolment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Twenty-eight-day ventilator-free days (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02167698, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2017.